

## Res. Asst. Sabin GÖKTAŞ AYDIN

### Personal Information

**Email:** sabinaaydin@medipol.edu.tr

**Web:** <https://avesis.medipol.edu.tr/sabinaaydin>

### Education Information

Expertise In Medicine, Istanbul University, İstanbul Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Turkey 2012 - Continues  
Undergraduate, Trakya University, Tıp Fakültesi, Tıp Pr., Turkey 2006 - 2012

### Foreign Languages

English, B2 Upper Intermediate

### Academic Titles / Tasks

Research Assistant, Istanbul University, İstanbul Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2012 - Continues

### Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Associations of serum uric acid levels and anthropometric parameters with non-alcoholic fatty liver disease in healthy individuals: innovative insights from a cross-sectional study**  
Aydin A., Goktas Aydin S.  
CURRENT MEDICAL RESEARCH AND OPINION, vol.40, no.2, pp.209-215, 2024 (SCI-Expanded)
- II. **Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide**  
Goktas Aydin S., Kutlu Y., Muglu H., Aydin A., Acikgoz Ö., Hamdard J., Karci E., Bilici A., Olmez Ö. F., Yildiz Ö.  
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.93, pp.71-78, 2024 (SCI-Expanded)
- III. **Impact of SPARC expression on treatment response of pembrolizumab and brain metastasis in patients with metastatic non-small cell lung cancer**  
GÖKTAŞ AYDIN S., BİLİCİ A., ÇALIŞ E., KUTLU Y., HAMDARD J., MUĞLU H., Fatih Olmez Ö. F., KARCI E., AÇIKGÖZ Ö.  
INTERNATIONAL IMMUNOPHARMACOLOGY, vol.124, 2023 (SCI-Expanded)
- IV. **Relationship between the change in tumour-infiltrating lymphocyte level and residual tumour after neoadjuvant chemotherapy in patients with locally advanced breast cancer**  
Erol V. B., GÖKTAŞ AYDIN S., BİLİCİ A., ÇAKIR A., AÇIKGÖZ Ö., ÖLMEZ Ö. F., BASIM P.  
Journal of Chemotherapy, vol.35, no.7, pp.662-670, 2023 (SCI-Expanded)
- V. **Survival outcomes of patients with oligometastatic non-small cell lung cancer who were treated with radical therapy: a multicenter analysis**  
Acikgoz O., Bilici A., Tataroglu Ozyukseler D., Göktas Aydın S., Selcukbiricik F., Rzazade R., Ölmez Ö. F., Caglar H. B.  
Turkish Journal of Medical Sciences, vol.53, no.4, pp.949-961, 2023 (SCI-Expanded)
- VI. **Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer.**  
GÖKTAŞ AYDIN S., Cakan Demirel B., BİLİCİ A., Topcu A., Aykan M. B., KAHRAMAN S., AKBIYIK I., Atci M. M., ÖLMEZ

Ö. F., Yaren A., et al.

Current medical research and opinion, vol.38, no.10, pp.1751-1758, 2022 (SCI-Expanded)

VII. **Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer**

İLHAN Y., TATLI A. M., Teker F., Onder A. H., Kose F., Geredeli C., Karaagac M., Kaplan M. A., İNANÇ M., GÖKTAŞ AYDIN S., et al.

International Journal of Gynecological Cancer, vol.32, 2022 (SCI-Expanded)

VIII. **Triple-negative breast cancer presented with metastasis to the heart as first sign of recurrence**

BAYRAMGİL A., BİLİCİ A., HAMDARD J., AÇIKGÖZ Ö., ŞEKER M., KILIÇASLAN F., KÖKSAL C., Buyukpınarbasılı N., MAMMADOV E., GÖKTAŞ AYDIN S., et al.

Breast Journal, vol.27, no.1, pp.56-57, 2021 (SCI-Expanded)

## Articles Published in Other Journals

I. **The Efficacy And Safety of CDK 4/6 Inhibitors Plus Endocrine Therapy With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2- Negative Metastatic Breast Cancer Patients**

acıkgöz o., Göktaş Aydın S., Bilici A., Kutlu Y., Muglu H., Karcı E., J., Mammadov E., ÖLMEZ Ö. F., yıldız Ö.

ACTA ONCOLOGICA TURCICA, vol.56, no.2, pp.153-160, 2023 (Peer-Reviewed Journal)

II. **The Optimal Treatment Approaches and Prognostic Factors in Elderly Patients with Advanced Stage Biliary Tract Tumors**

AYDIN S., BİLİCİ A., ÖLMEZ F. Ö., ÇAKAN B., Yılmaz C., Aydın A., Topçu A., AYKAN M. B., KAHRAMAN S., ATÇI M. M., et al.

ACTA ONCOLOGICA TURCICA, vol.56, no.1, pp.81-89, 2023 (Peer-Reviewed Journal)

III. **SURVIVAL EFFECT OF PALLIATIVE RADIOTHERAPY IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER DEVELOPING OLIGO-PROGRESSION UNDER ANTIANDROGEN TREATMENT**

Aydın S., Kutlu Y., Muglu H., Açıkğöz Ö., Aydın A., Bilici A., Ölmez Ö. F., Unal D., Karcı E., Yıldız Ö.

İstanbul Tıp Fakültesi Dergisi, vol.86, no.2, pp.117-122, 2023 (ESCI)

IV. **Treatment Management of Leptomeningeal and Brain Metastases as a First Recurrence Site in a Case with Germ Cell Testicular Tumor**

GÖKTAŞ AYDIN S., BİLİCİ A., ÇAKIR A., ÖLMEZ Ö. F., CİLA A., ÜNAL D.

Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi, vol.36, no.1, pp.77-80, 2022 (Peer-Reviewed Journal)

V. **FACTORS PREDICTING RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN LOCALLY ADVANCED GASTRIC CANCER LOKAL İLERİ MİDE KANSERİNDE NEOADJUVAN KEMOTERAPİYE YANITI ÖNGÖREN FAKTÖRLER**

Yildirim E., Bektaş S., GÖKTAŞ AYDIN S., Er A. M., Yanık I., Gümüşkaya P. Ö., Yılmaz B. U., BİLİCİ A., ÖNCEL M.

İstanbul Tıp Fakültesi Dergisi, vol.85, no.1, pp.41-50, 2022 (Scopus)